BASF stock hits Evonik hurdle as talks end without next meeting

BASF's pursuit of Evonik has hit another obstacle after senior executives from both companies held preliminary talks over the weekend. Evonik continues to reject BASF's increased offer, and no further meetings are currently scheduled, according to Reuters.

Deal remains without formal talks

The weekend meeting followed Evonik's rejection of BASF's improved approach at the end of October. The proposal values Evonik at EUR 11.18 billion, or EUR 24 per share. Evonik had rejected an earlier BASF proposal of EUR 22.15 per share in September.

Reuters said Evonik had asked BASF to explain the rationale for its bid, but the discussions did not move into formal takeover negotiations. The absence of a scheduled follow-up leaves BASF without a defined process for advancing the transaction.

Strategic value stays in focus

For BASF shareholders, the impasse keeps capital allocation and deal discipline at the center of the case. BASF has argued that combining the two German chemicals groups could strengthen their response to global competition, while Evonik continues to pursue its independent strategy.

The next investor test is whether BASF can persuade Evonik that the proposed combination creates sufficient value without weakening the buyer's financial discipline. Until then, the approach remains a strategic option rather than a defined transaction.

BASF stock traded at 53.93 euros on Lang & Schwarz at 18:48 CET on Monday, November 9, 2026.

European chemical shares remain sensitive to takeover expectations, industrial demand and capital allocation. The DAX market environment provides the broader German equity backdrop.

More news and analyses on BASF stock.